The FDA on August 14, 2024, approved NIKTIMVO®, a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic Graft-Versus-Host Disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. NIKTIMVO® is a product of Incyte Corporation.
Bottom Ad
Advertisement
Subscribe
